Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACmono LT
2024-513394-42-01Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- Jan 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease, sponsored by Erasmus MC. Primary endpoints: Renal function and proteinuria, Patient survival and 3 more. Planned start Jan 2025; status: authorised.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2024-513394-42-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513394-42-01.